SCHEMBL278947

SCHEMBL278947

CCOC(=O)CNCc1c(N)ccc(Cl)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PPID Q08752 3/20 0.42
PPIB P23284 1/20 0.42
PPIA P62937 1/20 0.42
PPIG Q13427 1/20 0.42
HTT P42858 2/20 0.40
MAPT P10636 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
LTA4H P09960 4/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NLRP3 Q96P20 1/20 0.37
KDM4E B2RXH2 2/20 0.36
LMNA P02545 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30505642 1.00 PPID (0.42) PPIDPPIBPPIAPPIGHTT
Hydrochloric Acid SCHEMBL5710126 0.99 PPID (0.41) PPIDPPIBPPIAPPIGHTT
Hydrochloric Acid SCHEMBL27767646 0.99 PPID (0.41) PPIDPPIBPPIAPPIGHTT
SCHEMBL11553376 0.90 LTA4H (0.34) PPIDPPIBPPIAPPIGALDH1A1
SCHEMBL11552559 0.87 SMN1; SMN2 (0.37) MAPTALDH1A1HPGDKMT2ATSHR
SCHEMBL11548859 0.87 ALDH1A1 (0.40) ALDH1A1HPGDKMT2ALTA4HTSHR
Hydrochloric Acid SCHEMBL5710314 0.86 SMN1; SMN2 (0.36) MAPTALDH1A1HPGDKMT2ATSHR
SCHEMBL16063626 0.84 HTT (0.48) PPIDPPIBPPIAPPIGHTT
SCHEMBL28208490 0.84 PPID (0.39) PPIDPPIBPPIAPPIGHTT
SCHEMBL7162754 0.83 ALDH1A1 (0.38) ALDH1A1HPGDKMT2ATSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116581427-B Long-acting new energy battery thermal management liquid 江苏艾德露环保科技有限公司 2023-09-01 CN claimed
CN-116581427-A Long-acting new energy battery thermal management liquid 江苏艾德露环保科技有限公司 2023-08-11 CN claimed
CN-108841363-B Pure electric vehicle cooling liquid and preparation method and application thereof 深圳市百顺源节能科技有限公司 2020-10-16 CN claimed
CN-108893180-A A kind of Novel wide temperature domain lubricating oil and preparation method thereof 张毅 2018-11-27 CN claimed
CN-103254197-A Preparation method of anagrelide hydrochloride UNIV HEILONGJIANG 2013-08-21 CN claimed
US-6653500-B2 Making ethyl N-(2,3-dichloro-6-nitrobenzyl)glycine from 2,3-dichlorobenzaldehyde, reducing the glycine compound using tin dichloride or a catalyst and cyclization of the corresponding iminoquinazoline compound SHIRE US INC. 2003-11-25 US claimed
US-20030060630-A1 Method for the manufacture of Anagrelide SHIRE US INC. 2003-03-27 US claimed
US-4208521-A Process for the preparation of imidazo[2,1-b]quinazolinones BRISTOL-MYERS COMPANY (US) 1980-06-17 US claimed
EP-3994238-B1 LUBRICATING COMPOSITIONS CONTAINING BASIC ASHLESS ADDITIVES LUBRIZOL CORP (US) 2024-03-13 EP disclosed
CN-116581427-B Long-acting new energy battery thermal management liquid 江苏艾德露环保科技有限公司 2023-09-01 CN disclosed
CN-116581427-B Long-acting new energy battery thermal management liquid 江苏艾德露环保科技有限公司 2023-09-01 CN disclosed
CN-116581427-A Long-acting new energy battery thermal management liquid 江苏艾德露环保科技有限公司 2023-08-11 CN disclosed
CN-116581427-A Long-acting new energy battery thermal management liquid 江苏艾德露环保科技有限公司 2023-08-11 CN disclosed
WO-2023144761-A1 PROCESS FOR THE PREPARATION OF ANAGRELIDE HYDROCHLORIDE MONOHYDRATE PIRAMAL PHARMA LIMITED (IN) 2023-08-03 WO disclosed
EP-0778258-A2 Process for the preparation of ethyl-n-(2,3 dichloro-6-nitrobenzyl) glycine ROBERTS LABORATORIES INC. (US) 1997-06-11 EP disclosed
EP-0514917-B1 Process for and 2-(cyanoimino)-quinazoline derivatives useful as intermediates in the preparation of 6,7-di-(chloro)-1,5-di(hydro)-imidazo-[2,1-b]quinazolin-2[3H]-one and process for preparing the 2-(cyanoimino)-quinazoline derivatives EGYT GYOGYSZERVEGYESZETI GYAR (HU) 1996-12-27 EP disclosed
US-5391737-A Process for the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one EGIS GYOGYSZERGYAR (HU) 1995-02-21 US disclosed
EP-0514917-A1 Process for and 2-(cyanoimino)-quinazoline derivatives useful as intermediates in the preparation of 6,7-di-(chloro)-1,5-di(hydro)-imidazo-[2,1-b]quinazolin-2[3H]-one and process for preparing the 2-(cyanoimino)-quinazoline derivatives EGIS GYOGYSZERGYAR (HU) 1992-11-25 EP disclosed
US-4208521-A Process for the preparation of imidazo[2,1-b]quinazolinones BRISTOL-MYERS COMPANY (US) 1980-06-17 US disclosed
US-4146718-A BLOOD PLATELET ANTIAGGREGATIVE AGENT BRISTOL-MYERS COMPANY (US) 1979-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060630-A1 Method for the manufacture of Anagrelide SUCLG2, PDCD2L, ICOSLG PPID 344/4885PPIB 464/4885PPIA 1264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.